Mikhail Blagosklonny is a major oncologist and cancer researcher currently working as a professor at the Roswell Park Cancer Institute (RPCI) in Buffalo, New York. After earning both his M.D. and PhD in cardiology and medicine at the First Pavlov State Medical University of St. Petersburg, Russia, Dr. Blagosklonny earned a job as an associate professor at the New York Medical College. Dr. Blagosklonny then quickly moved on to become a senior scientist at the Ordway Research Institute in Albany, NY. It wasn’t until 2009 that Dr. Blagosklonny took on the position of an oncology professor at RPCI. Check Mikhail’s profile in LinkedIn.
Dr. Blagosklonny is well known in the field of cancer research and oncology. Much of Dr. Blagosklonny’s work deals with the use of TOR signaling and rapamycin. Indeed, Dr. Blagosklonny is a major advocate of using rapamycin to extend life expectancy. A few other areas Dr. Blagosklonny is interested in include biogerontology (which is the study of biological aging) and targeted cancer therapies.
Just a few of the major publications Dr. Blagosklonny now serves as editor-in-chief for include Oncotarget, Cell Cycle, and Aging. In addition to serving as editor, Dr. Blagosklonny has written and published well over 170 researcher articles and reviews. Dr. Mikhail Blagosklonny is heavily cited in numerous publications in the fields of cancer study and oncology. Google Scholar officially says Dr. Blagosklonny has been cited in 26,323 cases. Dr. Blagosklonny hopes his work will lead to better care for cancer patients in the future. He also hopes his work will inspire the world to rethink how we think about aging and the treatment strategies we employ to help ease the burden of the aging process. Visit ResearchGate.Net to know more about Mikhail’s latest work.